IX Biopharma News

General Announcement-Press Release - iXB 401 Achieves 20x Higher Bioavailability Than Rybelsus in Preclinical Study

Nov 19 04:46 ET

General Announcement-Minutes of Extraordinary General Meeting Held on 17 October 2024

Nov 15 05:00 ET

General Announcement-Minutes of Annual General Meeting Held on 17 October 2024

Nov 15 04:57 ET

General Announcement-Formation of the Audit and Risk Committee and Reconstitution of the Board Committees

Oct 17 07:06 ET

IX Biopharma: REPL-Extraordinary/ Special General Meeting-Voluntary

Oct 17 07:00 ET

IX Biopharma: REPL-Annual General Meeting-Voluntary

Oct 17 06:53 ET

General Announcement-Press Release - iX Biopharma Appoints Dr. Brian Kennedy as New Scientific Advisor

Oct 14 05:39 ET

IX Biopharma: Extraordinary/ Special General Meeting-Voluntary

Sep 30 18:49 ET

Change - Announcement of Cessation-Retirement of Independent Director

Sep 30 18:45 ET

IX Biopharma: Annual General Meeting-Voluntary

Sep 30 18:41 ET

Financial Statements and Related Announcement-Auditor's Comments of Accounts

Sep 30 10:52 ET

General Announcement-Press Release - Business and Drug Development Updates - Wafermine and iXB 401

Sep 16 05:37 ET

General Announcement-Press Release - New Study Demonstrates that SL-NAD+ Delivers NAD+ into Cells

Sep 1 19:12 ET

Financial Statements and Related Announcement-Full Yearly Results

Aug 23 06:02 ET

General Announcement-Press Release - New Study Highlights CBD Wafer's Potential in Kidney Failure Patients

Aug 12 06:50 ET

Disclosure of Interest/ Changes in Interest of Substantial Shareholder(s)/ Unitholder(s)-Changes in Interest by Substantial Shareholder - Anson Properties Pte. Ltd.

Jul 24 05:51 ET

Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer-Disclosure of Interest/ Changes in Interest of Director - Albert Ho Shing Tung

Jul 24 05:47 ET

Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer-Disclosure of Interest/ Changes in Interest of Director - Eddy Lee Yip Hang

Jul 24 05:43 ET

IX Biopharma: REPL-Rights-Voluntary

Jul 22 07:57 ET

Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer-Disclosure of Interest/ Changes in Interest of Director - Albert Ho Shing Tung

Jul 22 07:44 ET